The Power of an Integrated Cell & Gene Therapy Supply Chain
The cell and gene therapy field is at a pivotal point, with expanding applications beyond oncology into immunology and other exciting new frontiers. This expansion will challenge logistics due to larger patient populations and variability between clinical sites.
In this Q&A, Matthew Frazzetta, Vice President of Global Accounts, BioServices at Cryoport Systems, discusses the company’s comprehensive end-to-end solutions and its crucial role in supporting CDMOs and therapeutic partners, including:
- How Cryoport Systems differs from other end-to-end offerings in the market
- The critical bioservices and logistics involved in handling and transporting high-value biologics
- Contingency plans to address potential supply chain disruptions
Download our info brief to discover how Cryoport Systems delivers next-generation, end-to-end solutions for managing the complexities of the advanced therapy supply chain.